EUVIMEDEUVIMED entdecken
Crossref

Management of Crohn’s Disease and Ulcerative Colitis Flare, Possibly Induced by Nivolumab Therapy: Two Cases and Review of The Literature

Gizem Dağcı

Journal of Enterocolitis · 2024

DOI: 10.14744/jenterocolitis.2024.240870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enterocolitis, 2024. Verfasst von Gizem Dağcı.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignancies can occur during the follow-up of patients with inflammatory bowel disease (IBD).Immune checkpoint inhibitors are increasingly used in the treatment of these malignancies due to their prolonged survival effects.Nivolumab, an immune checkpoint inhibitor, is used in cancer treatment.It works by blocking the PD-1 (programmed death) receptor on T cells, thereby enhancing the immune system's ability to fight cancer cells.However, this enhanced immune response can also lead to immune-related adverse events, including gastrointestinal complications.Herein, we present two patients diagnosed with inflammatory bowel disease flare on nivolumab therapy and review the literature.

Zitieren

APA

Dağcı, G. (2024). Management of Crohn’s Disease and Ulcerative Colitis Flare, Possibly Induced by Nivolumab Therapy: Two Cases and Review of The Literature. Journal of Enterocolitis. https://doi.org/10.14744/jenterocolitis.2024.240870

Vancouver

Dağcı G. Management of Crohn’s Disease and Ulcerative Colitis Flare, Possibly Induced by Nivolumab Therapy: Two Cases and Review of The Literature. Journal of Enterocolitis. 2024. doi:10.14744/jenterocolitis.2024.240870

BibTeX
@article{Dac2024,
  author = {Dağcı, Gizem},
  title = {Management of Crohn’s Disease and Ulcerative Colitis Flare, Possibly Induced by Nivolumab Therapy: Two Cases and Review of The Literature},
  journal = {Journal of Enterocolitis},
  year = {2024},
  doi = {10.14744/jenterocolitis.2024.240870}
}
Kostenlos starten →